Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-01-25
Based on 369 first isolates · MED-B · Cystitis (lower UTI) · 2025-01-26 → 2026-01-25
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (81 %–88 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Klebsiella pneumoniae (4 %), Pseudomonas aeruginosa (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
88 %
88 %
n = 24
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
88 %
n = 24
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
88 %
n = 24
ceftriaxone CRO
trend · Escherichia coli
82 %
75 %
n = 24
mecillinam MEC
trend · Escherichia coli lower UTI only
81 %
75 %
n = 24
ciprofloxacin CIP
trend · Escherichia coli
81 %
79 %
n = 24
78 %
71 %
n = 24
trimethoprim TMP
trend · Escherichia coli lower UTI only
73 %
75 %
n = 24
47 %
33 %
n = 24
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
8 %
n = 24
3 %
4 %
n = 24
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
4 %
n = 24

Most likely organisms for this profile

Escherichia coli
60 %
Klebsiella pneumoniae
11 %
Proteus mirabilis
8 %
Enterococcus faecalis
8 %
Citrobacter freundii
4 %
Staphylococcus aureus
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.